Lice Treatment Market Size To Expand at a Notable CAGR Of 6.6% During 2023-2032

Pune, India, April 2023/MRFR Press Release/- Market Research Future (MRFR) has published a cooked research report on the “Global Lice Treatment Market ” that contains information from 2018 to 2032. 

Market Highlights

The Global Lice Treatment Market is accounted to register a CAGR of 6.6% during the forecast period and is estimated to reach USD 0.2 billion by 2032.

The global lice treatment market refers to the market for products and services aimed at treating and controlling lice infestations in humans. Lice are parasitic insects that infest the scalp, body, and pubic hair, causing itching and discomfort. The market includes various treatment options such as over-the-counter (OTC) medications, prescription medications, natural remedies, and professional services.

Key Players

MRFR recognizes the following companies as the key players in the global Lice Treatment Market— Pfizer, Topaz Pharmaceuticals Inc, Sanofi, GlaxoSmithKline, Merck & Co. Inc, Taro Pharmaceuticals, Omega Pharma, Arbor Pharmaceuticals, ICB PHARMA, and Galderma Laboratories L.P.

Segment Analysis

The Global Lice Treatment Market has been segmented based on Type, Treatment, and Distribution Channel

The market segmentation of lice treatment, based on treatment, includes OTC products and prescription medications. The OTC products segment held the majority share in 2022, contributing to around ~62-65% of the market revenue of lice treatment. Over-the-counter treatments are in high demand in some geographical areas. Pyrethrin, a chemical compound obtained from chrysanthemum flowers, is the basis for OTC drugs. Over-the-counter drugs have always been popular due to their ease of access and low cost. Many consumers, primarily in developing and underdeveloped countries, use lice treatment. The demand for over-the-counter (OTC) products for treating lice is anticipated to increase due to the high prevalence and expanding child population who are more susceptible to infestation.

The lice treatment market segmentation, based on type, includes pediculosis capitis, pediculosis corporis, and pediculosis pubis. Pediculosis pubis dominated the market in 2022 and is expected to be the fastest-growing segment in the forecast period, 2023-2032. The market's expansion can be attributed to factors like the increasing prevalence of parasitic infection and the ease with which lice treatment products are available.

Distribution Channels have segmented the lice treatment market data into an online platform, hospitals, and clinics. The hospitals & clinics segment dominated the market in 2022 and is expected to be the fastest-growing segment in the forecast period, 2023-2030. One of the key factors influencing the rise in demand for lice treatment in hospitals and clinics is the rising prevalence of head lice among people worldwide. Increasing investment in developing medical formulas for successfully getting rid of these parasites is one factor that is anticipated to boost market growth over the coming years. Further accelerating segment market growth will be the ease with which lice treatment products can be found in hospitals and clinics.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Lice Treatment Market Research Report

Regional Analysis

The Global Lice Treatment Market, based on region, has been divided into Europe, North America, Asia-Pacific, and the Rest of the World. The North America Lice Treatment market is expected to grow at a significant CAGR during the study period, owing to increased awareness about head lice diagnosis and the availability of efficient products. The largest regional market share can be attributed primarily to the expansion of the infection pool and the population's increased proportion of children. Numerous companies offering modern health solutions are expected to drive regional development during the forecast period. Furthermore, increased product approvals contribute to market growth. For instance, in July 2020, the FDA of the United States granted permission for Xeglyze, a medication used to treat head lice in people six months of age and older. A clinical trial testing the medication's effectiveness in preventing head lice infestations led to the FDA's approval of the drug. According to the study, Xeglyze effectively riddled the scalps of live head lice in about 80% of patients.

The European lice treatment market is the second largest in the world. The primary drivers of the market's expansion are the rising level of awareness in the region and the presence of advanced medical and healthcare facilities with modern technology. However, Europe's vulnerable pediatric population is a substantial market driver for the lice treatment industry growth. Further, the German market of lice treatment held the largest market share, and the UK was the fastest-growing market in the European region.

The Asia-Pacific Lice Treatment Market is expected to grow at the fastest CAGR from 2022 to 2030 due to rising lice contamination in the region. Lice contamination is as high as 17% in India and 75% throughout Asia. On the other hand, the region's growing medical facilities and the existence of key market players have fueled the overall development of the market of lice treatment. Moreover, China’s market of lice treatment held the largest market share, and the Indian market was the fastest-growing in Asia-Pacific.

Key Findings of the Study

• The Global Lice Treatment Market is expected to reach USD 0.2 billion by 2032, at a CAGR of 6.6% during the forecast period.


• The Asia-Pacific Lice Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032 due to rising lice contamination in the region. Lice contamination is as high as 17% in India and 75% throughout Asia.


• The market segmentation of lice treatment, based on treatment, includes OTC products and prescription medications. The OTC products segment held the majority share in 2022, contributing to around ~62-65% of the market revenue of lice treatment.


• Pfizer, Topaz Pharmaceuticals Inc, Sanofi, GlaxoSmithKline, Merck & Co. Inc, Taro Pharmaceuticals, Omega Pharma, Arbor Pharmaceuticals, ICB PHARMA, and Galderma Laboratories L.P.